Objective:To compare the efficacy of long-acting and short-acting growth hormone therapies and their impact on the quality of life in children with short stature,providing a basis for clinical treatment selection.Methods:150 children with short stature were randomly divided into the control group,the long-acting treatment group and the short-acting treatment group using the sealed-envelope method.The control group received standardized healthy life guidance and nutritional support treatment.The long-acting treatment group received subcutaneous injection of long-acting growth hormone once a week.The short-acting treatment group received subcutaneous injection of short-acting growth hormone once a day.The clinical efficacy and quality of life of the three groups were evaluated after 6 months of continuous treatment.Results:After 6 months,height,height standard deviation score(HtSDS),and insulin-like growth factor 1(IGF-1)of the three groups increased compared with those before treatment(all P<0.05),the long-and short-acting groups showed significantly greater improvements than those of the control group(all P<0.05).However,there were with no significant differences between the two treatment groups(all P>0.05).Thyroid function and fasting blood glucose remained unchanged and within normal limits(all P>0.05).After treatment,quality of life did not significantly improve in the control group(P>0.05),while it significantly increased in both treatment groups compared to the control(all P<0.05),with no significant difference between the long-and short-acting groups(all P>0.05).Conclusion:Both long-and short-acting growth hormone therapies are equally effective in improving height and quality of life in children with short stature.
short staturechildrengrowth hormonequality of lifeoxytocin
维普
万方数据
